Ovarian cancer is the deadliest gynecologic malignancy globally and is increasing in incidence and mortality with currently more than 300,000 new cases and 200,000 deaths annually, according to data ...

Zentalis Pharmaceuticals, Inc.’s ZNTL share price has dipped by 21.25%, which has investors questioning if this is right time ...

Researchers at Peter Mac have uncovered potential new heredity genes that might be responsible for causing one of the most ...

Ovarian cancer, a deadly gynecologic malignancy, has seen a significant shift in its treatment paradigm with the introduction ...

Ovarian cancer, a deadly gynecologic malignancy, has seen a significant shift in its treatment paradigm with the introduction ...

High HSP60 expression in ovarian cancer is linked to poor prognosis and aggressive tumor features, including advanced FIGO stage and lymph node metastasis. Patients with elevated HSP60 levels ...

Due to his strong performance, Pro Football Focus gave him an extremely high grade. He ended up being the second-best graded player in the entire Wild Card round at 93.6. "The honor of the wild ...

However, studies investigating the relationship between COL1A1 expression levels and clinical characteristics of ovarian cancer (OC) remain limited ... All OC samples were pathologically confirmed to ...

Verastem, Inc. is on the verge of FDA approval for their combo therapy avutometinib-defactinib, targeting low-grade serous ovarian carcinoma ... At the high end, where 8000 people are alive ...

Low-grade serous ovarian cancer is highly recurrent and less sensitive to chemotherapy compared with high-grade serous ovarian cancer and approximately 6,000 to 8,000 women in the United States — as ...

Shares of Verastem Oncology VSTM rallied 40.9% on Tuesday after it announced that the FDA has accepted the new drug application (NDA) for its avutometinib/defactinib ...